Effects of glucose on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate

Journal of Pharmaceutical Sciences

Volumn 92, Issue 8, 2003, Pages 1604-1613

  Ahn, Choong Y ^a   Kim, Eun J ^a   Lee, Inchul ^b   Kwon, Jong W ^c   Kim, Won B ^c   Kim, Sang G ^a   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Dong A Pharmaceutical Company   (South Korea)

Author keywords

CZX; Glucose; OH CZX; Pharmacokinetics; Rats; U ARF

Indexed keywords

6 HYDROXYCHLORZOXAZONE; CHLORZOXAZONE; CYTOCHROME P450 2E1; GLUCOSE; UNCLASSIFIED DRUG; URANYL NITRATE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG DETERMINATION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; NONHUMAN; PLASMA PROTEIN BINDING; PROTEIN EXPRESSION; RAT;

EID: 0043212018     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10426     Document Type: Article

References (38)

1. Chen L, Yang CS. 1996. Effects of cytochrome P450 2E1 modulators on the pharmacokinetics of chlorzoxazone and 6-hydroxychlorzoxazone in rats. Life Sci 58:1575-1585.
2. Conney AH, Burns JJ. 1960. Physiological disposition and metabolic fate of chlorzoxazone (Paraflex) in man. J Pharmacol Exp Ther 128:340-343.
3. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. 1990. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 2E1. Chem Res Toxicol 3:566-573.
4. Desiraju RK, Renzi NL Jr, Nayak RK, Ng KT. 1983. Pharmacokinetics of chlorzoxazone in humans. J Pharm Sci 72:991-994.
5. Rockich K, Blouin R. 1999. Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats. Drug Metab Dispos 27:1074-1077.
6. Moon YJ, Lee AK, Chung HC, Kim EJ, Kim SH, Lee I, Kim SG, Lee MG. 2003. Effects of acute renal failure on the pharmacokintics of chlorzoxazone in rats, submitted for publication to Drug Metab Dispos, in press.
7. Chung HC, Kim SH, Lee MG, Kim SG. 2002. Increase in urea in conjunction with L-arginine metabolism in the liver leads to induction of cytochrome P450 2E1 (CYP2E1): The role of urea in CYP2E1 induction by acute renal failure. Drug Metab Dispos 30:739-746.
8. Son MH, Kang KW, Kim EJ, Ryu JH, Cho H, Kim SH, Kim WB, Kim SG. 2000. Role of glucose utilization in the restoration of hypophysectomy-induced hepatic cytochrome P450 by growth hormone in rats. Chem Biol Interact 127:13-28.
9. Kim SG, Kim EJ, Kim YG, Lee MG. 2001. Expression of cytochrome P450s and glutathione S-transferases in the rat liver during water deprivation: The effects of glucose supplementation. J Appl Toxicol 21:123-129.
10. Liu JH, Malone RS, Stallings H, Smith PC. 1996. Influence of renal failure in rats on the disposition of salicyl acyl glucuronide and covalent binding of salicylate to plasma proteins. J Pharmacol Exp Ther 278:277-283.
11. Kim SH, Shim HJ, Kim WB, Lee MG. 1998. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with uranyl nitrate-induced acute renal failure. Antimicrobial Agents Chemother 42:1217-1221.
12. Lowry OH, Rosebrough NG, Farr AL, Randall RJ. 1951. Protein measurement with Folin-phenol reagent. J Biol Chem 193:265-275.
13. Frye RF, Stiff DD. 1996. Determination of chlorzoxazone and 6-hydroxychorzoxazone in human plasma and urine by high-performance liquid chromatography. J Chromatogr B 686:291-296.
14. Lineweaver H, Burk D. 1934. The determination of enzyme dissociation constants. J Am Chem Soc 56: 658-666.
15. Liu PT, Ioannides C, Shavila J, Symons AM, Parke DV. 1993. Effects of ether anaesthesia and fasting on various cytochromes P450 of rat liver and kidney. Biochem Pharmacol 45:871-877.
16. Shim HJ, Lee EJ, Kim SH, Kim SH, Yoo M, Kwon JW, Kim WB, Lee MG. 2000. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 21:285-291.
17. Chiou WL. 1978. Critical evaluation of potential error in pharmacokinetics studies using the linear trapezoidal method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-549.
18. Gibaldi M, Perrier D. 1982. Pharmacokinetics, 2nd ed. New York: Marcel Dekker.
19. Kim SH, Choi YM, Lee MG. 1993. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21:1-17.
20. Chiou WL. 1979. New calculation method for mean apparent drug volume of distribution and application to rational dosage regimens. J Pharm Sci 68: 1067-1069.
21. Eatman FB, Colburn WA, Boxenbaum HG, Posmanter HN, Weinfeld RE, Ronfeld R, Weissman L, Moore JD, Gibaldi M, Kaplan SA. 1977. Pharmacokineties of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 5:481-494.
22. Chiou WL. 1980. New calculation method of mean total body clearance of drugs and its application to dosage regimens. J Pharm Sci 69:90-91.
23. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093-1095.
24. Mitruka BM, Rawnsley HM. 1982. Clinical Biochemical and Hematological Reference Values in Normal Experimental Animal and Normal Humans. 2nd ed. New York: Masson Publishing USA.
25. Lee MG, Chiou WL. 1983. Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623-640.
26. Wilkinson GR, Shand DG. 1975. Commentary: A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
27. Kashimoto T, Sakamoto W, Nakatani T, Ito T, Iwai K, Kim T, Abe Y. 1989. Cardiac output, renal blood flow and hepatic blood flow in rats with glycerol-induced acute renal failure. Nephron 53:353-357.
28. Carriere V, Goasduff T, Ratanasavanh D, Morel F, Gautier JC, Guillouza A, Beaune P, Berthou F. 1993. Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol 6:852-857.
29. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonzalez FJ. 1995. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 5:143-150.
30. Gorski JC, Jones DR, Wrighton SA, Hall SD. 1997. Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica 27:243-256.
31. Shimada T, Tsumura F, Tamazaki H. 1999. Prediction of human liver microsomal oxidation of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos 27:1274-1280.
32. Lewis DFV. 1996. Substrate specificity and metabolism, in Cytochromes P450 Structures, Function and Mechanism, Bristol, PA: Taylor & Francis, p. 123.
33. Mahnke A, Strotkamp D, Roos PH, Hanstein WG, Chabot GG, Nef P. 1997. Expression and inducibility of cytochrom P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver. Arch Biochem Biophys 337:62-68.
34. Debri K, Boobis AR, Davies DS, Edwards RJ. 1995. Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochem Pharmacol 50:2047-2056.
35. Hoen PA, Bijsterbosch MK, van Berkel TJ, Vermeulen NPE, Commandeur JNM. 2001. Midazolam is a phenobarbital-like cytochrome P450 inducer in rats. J Pharmacol Exp Ther 299:921-927.
36. Rekka E, Evdokimova E, Eeckhoudt S, Labar G, Calderon PB. 2002. Role of temperature on protein and mRNA cytochrome P450 3A (CYP3A) isozymes expression and midazolam oxidation by cultured rat precision-cut liver slices. Biochem Pharmacol 64:633-643.
37. Sierra-Santoyo A, Hernandez M, Albores A, Cebrian ME. 2000. Sex-dependent regulation of hepatic cytochrome P-450 by DDT. Toxicol Sci 54:81-87.
38. You L, Chan SK, Bruce JM, Archibeque-Engle S, Casanova M, Corton JC, Heck H. 1999. Modulation of testosterone-metabolizing hepatic cytochrome P450 enzymes in developing Sprague-Dawley rats following in utero exposure to p,p′-DDE. Toxicol Appl Pharmacol 158:197-205.